🇺🇸 FDA

Company profile · Sponsor

TESARO

TESARO Bio Netherlands B.V.

EAFACB7 · EMA pharma EU
Pipeline
6
Drugs
0
Patents
0

Quick answer

TESARO (EAFACB7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EAFACB7
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (6)

Search pipeline →

  1. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  2. Placebo is identical to the active drugs but without the active drug substance to maintain study blinding. Niraparib placebo tablets, Dostarlimab placebo infusion bags, JEMPERLI 500 mg concentrate for solution for infusion

    TESARO

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  3. Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

    TESARO

    Homologous recombination deficiency advanced ovarian cancer

    phase 3 small molecule active

    1 trial

  4. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

  5. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  6. Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is TESARO?

TESARO (EAFACB7) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does TESARO sponsor?

We track 6 ClinicalTrials.gov-linked programs for TESARO, including Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does TESARO company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.